ATE227573T1 - Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring - Google Patents

Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring

Info

Publication number
ATE227573T1
ATE227573T1 AT97101631T AT97101631T ATE227573T1 AT E227573 T1 ATE227573 T1 AT E227573T1 AT 97101631 T AT97101631 T AT 97101631T AT 97101631 T AT97101631 T AT 97101631T AT E227573 T1 ATE227573 T1 AT E227573T1
Authority
AT
Austria
Prior art keywords
camptothecin
oral
insoluble
water
lactone ring
Prior art date
Application number
AT97101631T
Other languages
English (en)
Inventor
Beppino C Giovanella
Hellmuth R Hinz
Anthony J Kozielski
John S Stehlin
Original Assignee
Stehlin Foundation For Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stehlin Foundation For Cancer filed Critical Stehlin Foundation For Cancer
Application granted granted Critical
Publication of ATE227573T1 publication Critical patent/ATE227573T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT97101631T 1993-01-15 1994-01-14 Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring ATE227573T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US284493A 1993-01-15 1993-01-15

Publications (1)

Publication Number Publication Date
ATE227573T1 true ATE227573T1 (de) 2002-11-15

Family

ID=21702794

Family Applications (3)

Application Number Title Priority Date Filing Date
AT97101631T ATE227573T1 (de) 1993-01-15 1994-01-14 Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring
AT02015200T ATE388706T1 (de) 1993-01-15 1994-01-14 Die verwendung von wasserunlöslichem s- camptothecin mit geschlossenem lactonring für die herstellung eines medikamentes zur behandlung von darmkrebs
AT94907804T ATE165003T1 (de) 1993-01-15 1994-01-14 Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT02015200T ATE388706T1 (de) 1993-01-15 1994-01-14 Die verwendung von wasserunlöslichem s- camptothecin mit geschlossenem lactonring für die herstellung eines medikamentes zur behandlung von darmkrebs
AT94907804T ATE165003T1 (de) 1993-01-15 1994-01-14 Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring

Country Status (9)

Country Link
EP (3) EP1250926B1 (de)
JP (1) JP3099128B2 (de)
AT (3) ATE227573T1 (de)
CA (1) CA2148822C (de)
DE (3) DE69435084T2 (de)
DK (3) DK0778024T3 (de)
ES (3) ES2301590T3 (de)
PT (1) PT1250926E (de)
WO (1) WO1994015604A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
ATE211142T1 (de) * 1989-09-15 2002-01-15 Res Triangle Inst Verfahren zur herstellung von 10,11-methylendioxy-20(rs)-camptothecin und 10,11-methylendioxy-20(s)-camptothecin-analog
US5422344A (en) * 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
EP1393730A3 (de) * 1991-11-15 2004-03-17 Smithkline Beecham Corporation Kombinationschemotherapy mit Topotecan und einer Platin-Koordinationsverbindung
CA2125293A1 (en) * 1991-12-10 1993-06-24 Randall Keith Johnson Treatment of colorectal cancer

Also Published As

Publication number Publication date
EP0678025A1 (de) 1995-10-25
DE69431731T2 (de) 2003-03-13
ATE165003T1 (de) 1998-05-15
EP0778024B1 (de) 2002-11-13
DE69431731D1 (de) 2002-12-19
WO1994015604A1 (en) 1994-07-21
ES2186812T3 (es) 2003-05-16
JPH08505626A (ja) 1996-06-18
EP1250926B1 (de) 2008-03-12
DK0678025T3 (da) 1998-10-07
JP3099128B2 (ja) 2000-10-16
EP0778024A1 (de) 1997-06-11
DE69435084D1 (de) 2008-04-24
DK1250926T3 (da) 2008-07-07
PT1250926E (pt) 2008-06-11
DK0778024T3 (da) 2002-12-23
ES2301590T3 (es) 2008-07-01
CA2148822A1 (en) 1994-07-21
EP0678025B1 (de) 1998-04-15
EP1250926A2 (de) 2002-10-23
DE69409633D1 (de) 1998-05-20
DE69435084T2 (de) 2009-03-19
ES2114681T3 (es) 1998-06-01
CA2148822C (en) 2001-03-27
DE69409633T2 (de) 1998-08-06
ATE388706T1 (de) 2008-03-15
EP1250926A3 (de) 2002-11-20

Similar Documents

Publication Publication Date Title
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ATE168560T1 (de) Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
ATE102838T1 (de) Zusammensetzungen zur behandlung von neoplasia mit gehalt an neoplasmushemmendem mittel und nebenwirkungen reduzierendem schutzmittel.
DK541189D0 (da) Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af interstitiel cystitis
DE69201660D1 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
ES2093357T3 (es) Metodo de tratamiento de la alopecia.
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
ATE227573T1 (de) Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
DE68910010D1 (de) Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin.
DE69233773D1 (de) Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
ES2129401T3 (es) Uso de un compuesto terapeutico para el tratamiento de bronquitis.
DK0556051T3 (da) Anvendelse af bilobalid samt derivater deraf til behandling af en infektion hos et individ og farmaceutiske præparater tilpasset denne anvendelse.
AU628492B2 (en) Improvements in chemical compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0778024

Country of ref document: EP

REN Ceased due to non-payment of the annual fee